Caribou Biosciences (CRBU) Cash from Investing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Investing Activities data on file, last reported at $24.0 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 51.43% year-over-year to $24.0 million in Q1 2026; TTM through Mar 2026 was $76.8 million, a 32.02% decrease from a year earlier, with the FY2025 full-year figure at $102.2 million, up 18.05% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $24.0 million, up from $18.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for CRBU reached as high as $49.4 million in Q1 2025 and fell as low as -$72.1 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged $3.0 million across 5 years, with a median of $15.9 million in 2024.
• Across the five-year window, Cash from Investing Activities tumbled 327659.09% in 2022 and surged 179.18% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $1.2 million in 2022, then tumbled by 2790.09% to -$31.5 million in 2023, then jumped by 150.61% to $15.9 million in 2024, then gained by 12.81% to $18.0 million in 2025, then surged by 33.47% to $24.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $24.0 million in Q1 2026, $18.0 million in Q4 2025, and $10.9 million in Q3 2025.